In the prostate adenocarcinoma, Ras/MAPK and PI3K/AKT/mTOR pathways display activating genetic alterations in more than 40% of primary tumours and in virtually all metastatic prostate tumours2, and phosphoproteomic studies confirmed a strong correlation in the activation of these two pathways5. This evidence concerns the gene AKT1 and prostate adenocarcinoma.